The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease

New approaches to the definition and treatment of hypertension have increased emphasis on reducing overall cardiovascular risk and on targeting the underlying mechanisms of cardiovascular disease. During the past several decades, renin–angiotensin–aldosterone system (RAAS) activation has emerged as...

Full description

Bibliographic Details
Main Authors: Dmitry Abramov, Peter E Carson
Format: Article
Language:English
Published: SAGE Publications 2012-09-01
Series:Journal of the Renin-Angiotensin-Aldosterone System
Online Access:https://doi.org/10.1177/1470320312443910
_version_ 1797288161958690816
author Dmitry Abramov
Peter E Carson
author_facet Dmitry Abramov
Peter E Carson
author_sort Dmitry Abramov
collection DOAJ
description New approaches to the definition and treatment of hypertension have increased emphasis on reducing overall cardiovascular risk and on targeting the underlying mechanisms of cardiovascular disease. During the past several decades, renin–angiotensin–aldosterone system (RAAS) activation has emerged as an important factor in the pathophysiology of endothelial dysfunction and cardiovascular disease (CVD). Angiotensin-converting enzyme inhibitors (ACEIs) have well-established efficacy for treating CVD, but their use may be limited by intolerable side effects, such as cough and angioedema. Angiotensin II receptor blockers (ARBs), a different class of RAAS inhibitors, are considered a viable alternative to ACEIs. Clinical trials have further elucidated the role of ARBs in CVD. This article reviews the mechanism of action of ARBs and selected clinical trials of ARBs in CVD.
first_indexed 2024-03-07T18:44:22Z
format Article
id doaj.art-561eb2a5a91447ed92ed437081307caf
institution Directory Open Access Journal
issn 1470-3203
1752-8976
language English
last_indexed 2024-03-07T18:44:22Z
publishDate 2012-09-01
publisher SAGE Publications
record_format Article
series Journal of the Renin-Angiotensin-Aldosterone System
spelling doaj.art-561eb2a5a91447ed92ed437081307caf2024-03-02T02:47:16ZengSAGE PublicationsJournal of the Renin-Angiotensin-Aldosterone System1470-32031752-89762012-09-011310.1177/1470320312443910The role of angiotensin receptor blockers in reducing the risk of cardiovascular diseaseDmitry AbramovPeter E CarsonNew approaches to the definition and treatment of hypertension have increased emphasis on reducing overall cardiovascular risk and on targeting the underlying mechanisms of cardiovascular disease. During the past several decades, renin–angiotensin–aldosterone system (RAAS) activation has emerged as an important factor in the pathophysiology of endothelial dysfunction and cardiovascular disease (CVD). Angiotensin-converting enzyme inhibitors (ACEIs) have well-established efficacy for treating CVD, but their use may be limited by intolerable side effects, such as cough and angioedema. Angiotensin II receptor blockers (ARBs), a different class of RAAS inhibitors, are considered a viable alternative to ACEIs. Clinical trials have further elucidated the role of ARBs in CVD. This article reviews the mechanism of action of ARBs and selected clinical trials of ARBs in CVD.https://doi.org/10.1177/1470320312443910
spellingShingle Dmitry Abramov
Peter E Carson
The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease
Journal of the Renin-Angiotensin-Aldosterone System
title The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease
title_full The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease
title_fullStr The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease
title_full_unstemmed The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease
title_short The role of angiotensin receptor blockers in reducing the risk of cardiovascular disease
title_sort role of angiotensin receptor blockers in reducing the risk of cardiovascular disease
url https://doi.org/10.1177/1470320312443910
work_keys_str_mv AT dmitryabramov theroleofangiotensinreceptorblockersinreducingtheriskofcardiovasculardisease
AT peterecarson theroleofangiotensinreceptorblockersinreducingtheriskofcardiovasculardisease
AT dmitryabramov roleofangiotensinreceptorblockersinreducingtheriskofcardiovasculardisease
AT peterecarson roleofangiotensinreceptorblockersinreducingtheriskofcardiovasculardisease